All In Biotech

Drug Trial Radar · NCT07166094

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Nov 28, 2025

Primary completion

Aug 2029

Study completion Nov 2029

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (50:50) chance of getting either Rina-S or a chemotherapy agent as treatment in this study. The study duration will be approximately 3 years. The treatment duration will be different for every participant, but an average of 4 to 6 months is expected. All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s).

Conditions

  • Endometrial Cancer
  • Recurrent or Progressive Endometrial Cancer

Interventions

  • Rina-SDrug

    Intravenous (IV) infusion.

  • ICDrug

    * Paclitaxel: IV infusion * Doxorubicin: IV bolus injection/infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Criteria in Solid Tumors (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years
  2. Overall Survival (OS)Time frame: Up to approximately 3 years

Locations

178 sites in 19 countries. Site status is shown where the registry gives one.

  • USAH Mitchell Cancer Inst

    Mobile, Alabama · Recruiting

  • HonorHealth Research Inst

    Phoenix, Arizona · Recruiting

  • Kaiser Permanente SoCal

    Irvine, California · Recruiting

  • CPMC Research Institute

    San Francisco, California · Recruiting

  • Norwalk Hospital

    Danbury, Connecticut · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Norwalk Hospital

    Norwalk, Connecticut · Recruiting

  • MedStar Washington Hospital

    Washington D.C., District of Columbia · Recruiting

  • SMH - Sarasota - Main Campus

    Sarasota, Florida · Recruiting

  • Women's Care - 9th Ave

    St. Petersburg, Florida · Recruiting

  • Women's Care - Armenia Ave

    Tampa, Florida · Recruiting

  • Emory Winship Cancer Inst.

    Atlanta, Georgia · Recruiting

  • Emory Winship Cancer Inst.

    Atlanta, Georgia · Recruiting

  • Northside Hospital Atlanta

    Atlanta, Georgia · Recruiting

  • Emory Winship Cancer Inst./Emory Decatur Hospital

    Decatur, Georgia · Recruiting

  • Endeavor Health NorthShore

    Evanston, Illinois · Recruiting

  • OLOL Cancer Institute

    Baton Rouge, Louisiana · Recruiting

  • LSU Health New Orleans

    New Orleans, Louisiana · Recruiting

  • Trials365, LLC

    Shreveport, Louisiana · Recruiting

  • Sinai Hospital

    Baltimore, Maryland · Recruiting

  • William Kahlert Reg. Can. Ctr

    Westminster, Maryland · Recruiting

  • UMass Memorial Medical Ctr

    Worcester, Massachusetts · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Recruiting

  • USOR - Minnesota Oncology-Coon Rapids Clinic

    Coon Rapids, Minnesota · Recruiting

  • USOR - Minnesota Oncology/ Coon Rapids Clinic

    Coon Rapids, Minnesota · Recruiting

  • USOR - Minnesota Oncology - Edina Clinic

    Edina, Minnesota · Recruiting

  • USOR - Minnesota Oncology/Edina Clinic

    Edina, Minnesota · Recruiting

  • USOR - Minnesota Oncology/ Maple Grove Clinic

    Maple Grove, Minnesota · Recruiting

  • USOR - Minnesota Oncology-Maplewood Clinic

    Maplewood, Minnesota · Recruiting

  • USOR - Minnesota Oncology/ Maplewood Clinic

    Maplewood, Minnesota · Recruiting

  • USOR - Minnesota Oncology/ Minneapolis Clinic

    Minneapolis, Minnesota · Recruiting

  • USOR - Minnesota Oncology

    Minneapolis, Minnesota · Recruiting

  • USOR - Minnesota Oncology/ Woodbury Clinic

    Woodbury, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Morristown Medical Center

    Morristown, New Jersey · Recruiting

  • Atlantic Health - Overlook MC

    Summit, New Jersey · Recruiting

  • Holy Name Medical Center

    Teaneck, New Jersey · Recruiting

  • NYU Laura and Isaac Perlmutter Cancer Center - 34th Street

    New York, New York · Recruiting

  • Perlmutter CC NYU Langone LI

    New York, New York · Recruiting

  • Atrium Health LCI - Morehead

    Charlotte, North Carolina · Recruiting

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.